Huawei, a global information and communications technology provider, and WuXi AppTec, a global open-access R&D platform, have launched the China Precision Medicine Cloud. This platform brings together three unique elements: Huawei's capabilities and national network for cloud computing, the medical innovation expertise of WuXi AppTec and the experience of its subsidiary WuXi NextCODE in organizing, mining and sharing genomics big data.
The technology in this platform underpins data infrastructure across China and the largest and most advanced precision medicine projects around the world—from national genome projects to gene discovery, clinical diagnostics, targeted pharmaceutical development and scientific wellness. It will link scientific excellence and data from across China through a secure nationwide network and governmental, medical, academic and industry collaborations.
A unified cloud that enables both clinical and research genomics in real time, online is the foundation for delivering precision medicine efficiently at national scale. WuXi AppTec and Huawei will follow the guidance of the China Food and Drug Administration (CFDA) and work closely with partner life-science cloud providers to develop the data standards and exchange framework required to deliver the China PMI. WuXi AppTec and WuXi NextCODE solutions already meet U.S. CAP and CLIA standards and include HIPAA-compliant DNAnexus technology delivering the precisionFDA in the U.S., so that in implementing guidelines developed by the CFDA the China Precision Medicine Cloud will be well positioned for global compliance and collaboration.
"We are focused on unlocking the full potential of precision medicine in China," said Hannes Smarason, COO of WuXi NextCODE. "This is a big data challenge, and what we are creating here is the fusion of the largest scale genomics platform and the leading China cloud network. It is a win-win for China Precision Medicine and its impact here and around the world."
